SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.66+2.8%Jan 30 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (8743)2/16/1999 1:25:00 PM
From: aknahow  Read Replies (2) of 17367
 
Bluegree, I really have no idea of what you are trying to say. Neuprex may or may not work. The quickest way to get it available is to prove it works. Since Meningococcal sepsis is rare in the U.S. designing a trial with a sufficient number of subjects must have ben a daunting task. Apparently in what I see as an effort to assure XOMA that the trial would not run on for years and years an agreement was reached that the trial could be halted, regardless of how small the total number of subjects was if a mortality target was reached.

This seems to me to be an effort to speed things up not slow them down.

Please give this a rest. Lets first see if Neuprex works, and if the FDA takes months, and months to approve it, then lets protest. But not now!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News